Future studies should validate composite immune panels that combine interferon signatures, cytokine profiles (e.g., IP-10), neutralizing antibody titers, and T-cell assays and link these measures to clinical outcomes, such as breakthrough infections, hospitalizations, and lupus flares. The gene discussed is CXCL10; the disease is infection.